Pharmacopeia extends agreement with Schering-Plough

By Lisa Kerner

Charlotte, N.C., Sept. 28 - Pharmacopeia Drug Discovery Inc. and Schering-Plough extended their collaboration through April 2007.

Pharmacopeia president and chief executive officer Leslie J. Browne made the announcement during remarks at today's UBS Global Life Sciences Conference in New York.

Schering-Plough will continue to pay Pharmacopeia research funding, as well as pre-clinical, clinical and regulatory milestones.

The goal of the collaboration remains unchanged: to develop therapeutic candidates for the Schering-Plough pipeline.

Browne also noted the importance of his company's DARA (dual acting receptor angiotensin and endothelin receptor antagonist) product to Pharmacopeia's operation. DARA is currently in preclinical development for the treatment of hypertension and diabetic neuropathy.

The company plans to file an Investigational New Drug Application with the Food and Drug Administration for DARA by the first quarter of 2007, Browne said.

Pharmacopeia develops novel therapeutics in Princeton, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.